Rotunda Hospital

At Rotunda Hospital, clinical research in female urogenital diseases and pregnancy complications focuses on improving outcomes for women with antiphospholipid antibodies and related obstetric risks. These studies are designed to assess whether targeted treatments can support healthier pregnancies and reduce complications.

• Evaluating treatment effectiveness in women with antiphospholipid antibodies
• Studying approaches to improve pregnancy outcomes
• Exploring therapies for immune-related obstetric complications

This work also connects with broader immune system disease research, reflecting the site’s interest in conditions where maternal health and fetal wellbeing are closely linked.

Research in hemolytic disease of the fetus and newborn is a major focus at the Rotunda Private Clinics. The trials aim to test new ways to reduce the risk of fetal anemia and improve survival and health outcomes for babies affected by severe antibody-mediated disease during pregnancy.

• Testing a new therapy for severe fetal anemia risk
• Improving care for pregnancies affected by HDFN
• Assessing strategies to support live birth outcomes

This area sits at the intersection of pregnancy complications and immune-mediated disease, with a strong emphasis on protecting both mother and baby.

The site also supports studies in nervous system diseases, including moderate-severe hypoxic-ischaemic encephalopathy in newborns. These trials are focused on evaluating whether emerging treatments can better protect the infant brain and improve early recovery after oxygen-related injury at birth.

• Testing a potential therapy for newborn encephalopathy
• Assessing safety and tolerability in acute neonatal care
• Exploring ways to improve neurological outcomes

This research reflects a strong commitment to advancing care for critically ill newborns through neonatal medicine and brain-protective treatment strategies.

Clinical trials in cardiovascular diseases at Rotunda Hospital include work on patent ductus arteriosus in extremely premature infants. The research is aimed at improving treatment effectiveness and reducing complications linked to duct-related heart problems in very small babies.

• Comparing treatment approaches for PDA in premature infants
• Testing a combination therapy to improve duct-related outcomes
• Seeking better ways to lower serious neonatal complications

These studies are part of a wider effort to refine neonatal cardiovascular care and support healthier early-life outcomes.